Caris Life Sciences (CAI) Net Income towards Common Stockholders (2024 - 2026)

Caris Life Sciences' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 99.6% year-over-year to -$510000.0; the TTM figure through Mar 2026 stood at -$411.4 million (down 10.85% YoY), while the FY2025 annual figure was -$538.0 million, down 42.22% from the prior year.
• Net Income towards Common Stockholders was -$510000.0 for Q1 2026 at Caris Life Sciences, down from $82.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $82.0 million in Q4 2025 to a low of -$517.2 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$97.8 million across 3 years, with a median of -$75.9 million in 2024.
• Biggest YoY gain for Net Income towards Common Stockholders was 232.3% in 2025; the steepest drop was 476.07% in 2025.
• A 3-year view of Net Income towards Common Stockholders shows it stood at -$61.9 million in 2024, then surged by 232.3% to $82.0 million in 2025, then sank by 100.62% to -$510000.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$510000.0 (Q1 2026), $82.0 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.